These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29023878)

  • 1. Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals.
    Dimitroglou J; Zampetas D; Vasilieva L; Koullias E; Ketikoglou I; Alexopoulou A; Dourakis SP
    Aliment Pharmacol Ther; 2017 Nov; 46(9):908-909. PubMed ID: 29023878
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals - Authors' reply.
    Mücke MM; Mücke VT; Vermehren J
    Aliment Pharmacol Ther; 2017 Nov; 46(9):909-910. PubMed ID: 29023880
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: adoption of uniform nomenclature is crucial for estimating the true risk of HBV reactivation in patients treated with direct-acting antivirals for hepatitis C.
    Mücke MM; Mücke VT; Vermehren J
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1573-1574. PubMed ID: 29878415
    [No Abstract]   [Full Text] [Related]  

  • 4. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
    Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
    J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.
    Aggeletopoulou I; Konstantakis C; Manolakopoulos S; Triantos C
    World J Gastroenterol; 2017 Jun; 23(24):4317-4323. PubMed ID: 28706414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
    Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
    Thibault V
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):145-147. PubMed ID: 29371018
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: hepatitis B virus reactivation in patients with chronic hepatitis C during direct-acting anti-viral therapy.
    Huang R; Yan X; Xia J; Wang J; Wu C
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1558. PubMed ID: 28503862
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply.
    Londoño MC; Carrión JA; Forns X
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1559-1560. PubMed ID: 28503869
    [No Abstract]   [Full Text] [Related]  

  • 14. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?
    Galli C; Orlandini E; Penzo L; Badiale R; Caltran G; Valverde S; Gessoni G
    J Med Virol; 2008 Jun; 80(6):974-9. PubMed ID: 18428144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.
    Agrawal B; Kumar R
    World J Gastroenterol; 2016 Jul; 22(25):5623-6. PubMed ID: 27433078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections.
    Temel T; Cansu DÜ; Korkmaz C; Kaşifoğlu T; Özakyol A
    Int J Rheum Dis; 2015 Jan; 18(1):40-5. PubMed ID: 25195983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.